Quest Diagnostics (DGX) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-26) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion with CAM on DIS accounts receivable contractual allowances

Fiscal Year: 2025 (ended December 31, 2025)

One-line verdict: Quest Diagnostics delivered its cleanest operating year in a decade — revenues grew 11.8% to $11.0B, CFFO surged 41.4% to $1.9B, and PwC issued an unqualified audit opinion. The Beneish M-Score of -2.67 clears the manipulation threshold and the Altman Z-Score of 3.55 puts DGX squarely in the safe zone. The F grade is mechanical, driven by two balance sheet facts the engine cannot ignore: goodwill plus intangibles of $10.6B total 148% of equity after the LifeLabs, Lenco, PathAI Diagnostics, and Haystack Oncology acquisitions, and cash of just $420M covers only 6% of the $6.6B debt load. In other words — Quest is generating cash, growing the top line, and the accounting is clean, but the balance sheet is fully deployed and the margin for error is thin. PwC's one Critical Audit Matter focuses on contractual allowances for payer receivables, which is the perennial estimation area for a diagnostic-information business where payer denials and patient price concessions drive true realized revenue.

The Cleanest Operating Year in a Decade

The 10-K's MD&A puts the growth in clear terms: "Net Revenues. Net revenues for the year ended December 31, 2025 increased by 11.8% compared to the prior year. For the year ended December 31, 2025, organic growth was 5.3% compared to the prior year."

The segment breakdown in the MD&A shows:

The 12.3% requisition volume growth of which only 3.4% was organic tells you the rest came from acquisitions — chiefly LifeLabs (completed August 23, 2024), Lenco Diagnostics (February 2024), PathAI Diagnostics (June 2024), and Haystack Oncology (June 2023). The 10-K describes Haystack Oncology as "a cancer testing company that has developed a highly sensitive testing technology for detecting minimal-residual disease (MRD) by circulating tumor DNA due to residual or recurring cancer." It also notes that Quest "acquired select clinical testing and dialysis-related water testing assets of Fresenius Medical Care's wholly-owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the United States" and "entered into a joint venture with Corewell Health" in Michigan.

Two Segments: DIS (Diagnostic Information Services) and DS (Diagnostic Solutions)

The 10-K reports two businesses:

DIS (Diagnostic Information Services) — The core commercial clinical laboratory, $10,785M of 2025 revenue (97.7% of total). This is the reference laboratory competing with "Laboratory Corporation of America Holdings, Inc." as the 10-K identifies Quest's "largest commercial clinical laboratory competitor."

DS (Diagnostic Solutions) — Products and risk assessment services, $250M of 2025 revenue. The 10-K notes this segment is a smaller specialty business and is also subject to goodwill impairment testing: "DIS business; Risk assessment services business, which is part of our DS businesses."

Quest acquired Lenco, PathAI Diagnostics, and LifeLabs — Canada's largest community lab — during 2024. From the 10-K's acquisition footnote: "Net assets acquired $1,053... $300... $230... $200... $183... $248... $2,214." LifeLabs is the largest component of the 2024 acquisition spree. The additional 2025 acquisition cohort brought in "acquisitions of Lenco and PathAI Diagnostics" as the 10-K specifies.

Balance Sheet: $10.6B Goodwill+Intangibles on $7.2B Equity

The screening engine flags: "Goodwill+Intangibles $10.6B = 148% of equity. Over 50%." This is a FAIL on check D1.

The $8.9B in goodwill is the cumulative cost of over a decade of acquisitions — Cleveland HeartLab, ReproSource, Blueprint Genetics, Haystack Oncology, PathAI Diagnostics, Lenco, LifeLabs, and several smaller tuck-ins. The 10-K's impairment policy explains the testing approach: "The DIS reporting unit components have been aggregated into a single reporting unit because they have similar economic characteristics, including similarities in financial performance, nature of products or services, nature of production processes and types of customers." It adds: "On a quarterly basis, we perform a review of our business to determine if events or changes in circumstances have occurred which could have a material adverse effect on our fair value and our goodwill."

No impairment was recognized in 2025. But the 10-K explicitly lists the triggers to monitor: "(a) macroeconomic conditions; (b) industry and market considerations; (c) cost factors; (d) overall financial performance; (e) other relevant entity-specific events; (f) events affecting a reporting unit; and (g) a sustained decrease in share price."

Debt vs. Cash

The screening engine flags: "Cash $0.4B covers only 6% of debt $6.6B." This is a FAIL on check C4. Quest operates with a deliberately low cash balance — common for a stable cash-generative business that uses its revolver and commercial paper for working capital — but the engine still registers the concentration.

The 10-K references the August 2024 issuance: "the issuance of $1.85 billion of senior notes during August 2024, partially offset by the repayment in full of the outstanding indebtedness under our $300 million of 4.25% senior notes at maturity and $151 million of share repurchases of our common stock." The August 2024 issuance funded the LifeLabs acquisition ($1.35 billion) plus working capital. 2025 used "$410 million under our secured receivables credit facility."

Debt/EBITDA is 3.0x and interest coverage is 5.6x — healthy on the leverage check (D2 passes), despite the low cash buffer.

Cash Flow: Where the Engine Gives Full Marks

The screening engine confirms on C1: "CFFO/NI = 1.90. Profits backed by cash." On C2: "FCF $1.4B, FCF/NI = 1.37." On C3: "Accruals ratio = -5.5%. Low accruals." All three cash-quality checks pass.

CFFO surged 41.4% from $1,334M to $1,886M — well ahead of the 11.8% revenue growth. The 10-K attributes this to favorable working capital changes and the acquisitions' contributions. FCF of $1.36B is healthy on an $11.0B revenue base (12.3% FCF margin).

CapEx increased 24% year-over-year — the screening engine flags this on B2 as a WATCH: "CapEx growth 24.0% is >2x revenue growth 11.8%." This is the only watch item in the screen and reflects investment in automation, LifeLabs integration and new Corewell Health joint-venture facilities. Not a red flag on its own.

Auditor's Critical Audit Matter — Contractual Allowances

PricewaterhouseCoopers LLP issued an unqualified opinion on the consolidated financial statements and "audited the Company's internal control over financial reporting as of December 31, 2025." PwC identified one Critical Audit Matter: Valuation of Diagnostic Information Services (DIS) Business Accounts Receivable — Contractual Allowances.

The 10-K reproduces PwC's description: "management estimates the amount of consideration the Company expects to be entitled to receive from payer customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials) and patient price concessions. The Company's consolidated accounts receivable, net of allowance for credit losses, balance as of December 31, 2025 was $1,408 million, of which a significant portion related to the DIS business. Net revenues recognized from healthcare insurers and government payers consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience..."

This is the standard CAM for a diagnostic-information business: payer behavior (denials, appeals, price concessions) determines realized revenue, and the gap between billed and collected is material. PwC's audit procedures focused on historical denial patterns and collection experience.

A healthy signal: DSO remains at 47 days (2024: 48) — the screening engine passes A1 with "DSO 47 days, change -2 days YoY." Receivables quality is improving, not deteriorating.

M-Score: Clean Manipulation Signal

The F-Score (Dechow et al.) returns 1.44, placing the probability of misstatement at just 0.53% — well below the 1% normal threshold.

Altman Z-Score comes in at 3.55 in the safe zone, with healthy contributions from X2 (retained earnings/TA = 0.616), X3 (EBIT/TA = 0.098), and X4 (equity/liabilities = 0.802).

The 18-Point Screening

Revenue Quality

Expense Quality

Cash Flow Quality

Balance Sheet

Acquisition Risk

Manipulation Score

Additional Scores: F-Score probability of misstatement 0.53% (very low). Altman Z-Score 3.55 (safe zone).

Key Risks from the 10-K

1. Payer Reimbursement Pressure (PAMA) — The 10-K describes the ongoing impact of the Protecting Access to Medicare Act: "Medicare Act of 2014 (PAMA). Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018-2020. Unfortunately, by relying on laboratory reported data alone in 2017, CMS did not receive comprehensive and representative data needed to set Medicare rate[s]..." The 10-K adds that CMS "has refreshed its strategy" for laboratory reimbursement. PAMA cycle rebasing remains a recurring pressure.

2. Highly Competitive and Fragmented Market — From the 10-K: "The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other commercial clinical laboratories, including smaller regional and local commercial clinical laboratories and specialized advanced laboratories, hospital-affiliated laboratories and physician-office laboratories." Also: "Competition is emerging from new technologies (e.g., digital pathology) and growing from non-traditional competitors (e.g., a government agency; providers of consumer-initiated testing)." Hospital vertical integration and private equity capital are explicitly called out.

3. Regulatory/Political Uncertainty — The 10-K warns: "The political environment impacting healthcare regulation in the United States continues to be uncertain. The services that we offer and our result of operations could be adversely affected by legislative, enforcement, regulatory and public policy changes at the federal or state level, many of which we cannot anticipate at this time. There continues to be pressures on and uncertainty surrounding the U.S. federal government's budget, and potential changes in budgetary priorities..." Medicare, Medicaid, and ACA policy changes all flow through DGX's top line.

4. Goodwill Concentration in the DIS Unit — The $8.9B of goodwill sits almost entirely in the aggregated DIS reporting unit. Because the DIS business is aggregated, an impairment event would likely affect a large portion of goodwill at once rather than a single acquired subunit. The 10-K's quarterly review protocol is a positive governance signal; the concentration risk is still structural.

5. Acquisition Integration Execution — The 2024 acquisition cohort (LifeLabs, Lenco, PathAI, Spectra) is still being integrated. LifeLabs adds Canadian exposure to a business historically concentrated in the U.S. Integration risk is real but the 2025 organic growth of 3.4% suggests the core business is holding steady independent of acquisition contribution.

6. Contractual Allowance Estimation — The CAM identified by PwC (contractual allowances on DIS receivables) is the single-largest accounting estimate affecting revenue. Any systematic change in payer denial rates or collection patterns would flow directly through to reported revenue.

Summary

Grade: F. Clean accounting, clean operating year, structural balance sheet stress.

Quest Diagnostics had a very good 2025 by operational measures: 11.8% revenue growth (3.4% organic), operating income up to $1.56B, diluted EPS of $8.75, CFFO of $1.89B, and PwC issued an unqualified opinion with a CAM that is standard for the industry. The Beneish M-Score of -2.67 is clean; the F-Score probability of misstatement is 0.53%; Altman Z-Score is 3.55 in the safe zone. None of the forensic indicators suggest accounting manipulation.

The F grade is driven by two purely structural facts. First, goodwill plus intangibles of $10.6B is 148% of equity — the result of a decade of tuck-in acquisitions culminating in the 2024 LifeLabs deal. DGX is a serial acquirer and the cumulative capital deployed is now larger than the recorded equity base. Second, cash of $420M covers only 6% of $6.6B in total debt — Quest runs a deliberately low-cash balance sheet and relies on revolver access and commercial paper for liquidity. That is normal for a stable cash-generative business, but the engine registers concentration risk.

The real questions for the next 24 months are about the macro environment, not the books. PAMA reimbursement rebasing remains a recurring headwind. Hospital vertical integration is shrinking the addressable market. The 2024 acquisition cohort (LifeLabs in Canada especially) still has integration work to do. And the business generates enough free cash ($1.36B in 2025) that the debt load, while sizable, is serviceable.

A reader looking to understand Quest Diagnostics should read the 10-K's Risk Factors section on PAMA and competitive dynamics, read PwC's CAM on contractual allowances (the single biggest accounting estimate), and follow the quarterly organic growth number — 3.4% in 2025 is modest but positive, and PAMA cycle changes could move that number materially.

**Disclaimer**: This report is based on Quest Diagnostics' 2025 10-K (SEC EDGAR, filed 2026-02-26) and public financial data. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags. Grade F means major red flags were detected that require serious investigation before proceeding.